TIM-3, encoded by the HAVCR2 gene, has recently emerged as an immunotherapy target, as it is often co-expressed alongside PD-1 on the most dysfunctional and exhausted population of tumor-infiltrating T-cells [21,22]. The gene discussed is HAVCR2; the disease is neoplasm.